Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wan-Ju Lee

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Pharmacoeconomics - Open|June 9, 2023
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative ColitisEdward V Loftus, Ashwin N Ananthakrishnan, Wan-Ju Lee, et al.
Gastro Hep Advances|April 7, 2025
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's DiseaseBrian G Feagan, Remo Panaccione, Stefan Schreiber, et al.
Gastro Hep Advances|January 13, 2025
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's DiseaseBrian G Feagan, Jean-Frederic Colombel, Remo Panaccione, et al.
Dermatology and Therapy|July 14, 2025
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
The British Journal of Dermatology|June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Journal of Crohn'S & Colitis|June 5, 2024
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's DiseaseSubrata Ghosh, Brian G Feagan, Rogério Serafim Parra, et al.
Scientific Reports|May 12, 2018
Real-world use of ranibizumab for neovascular age-related macular degeneration in TaiwanYi-Sheng Chang, Wan-Ju Lee, Chen-Chee Lim, et al.
Journal of Crohn'S & Colitis|June 2, 2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyMarc Ferrante, Brian G Feagan, Julián Panés, et al.
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Pharmacoeconomics - Open|June 9, 2023
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative ColitisEdward V Loftus, Ashwin N Ananthakrishnan, Wan-Ju Lee, et al.
Gastro Hep Advances|April 7, 2025
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's DiseaseBrian G Feagan, Remo Panaccione, Stefan Schreiber, et al.
Gastro Hep Advances|January 13, 2025
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's DiseaseBrian G Feagan, Jean-Frederic Colombel, Remo Panaccione, et al.
Dermatology and Therapy|July 14, 2025
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
The British Journal of Dermatology|June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Journal of Crohn'S & Colitis|June 5, 2024
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's DiseaseSubrata Ghosh, Brian G Feagan, Rogério Serafim Parra, et al.
Scientific Reports|May 12, 2018
Real-world use of ranibizumab for neovascular age-related macular degeneration in TaiwanYi-Sheng Chang, Wan-Ju Lee, Chen-Chee Lim, et al.
Journal of Crohn'S & Colitis|June 2, 2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyMarc Ferrante, Brian G Feagan, Julián Panés, et al.
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Pageof 5